Veeva Systems and Crossix Solutions have announced that they have entered into a definitive agreement for Veeva to acquire Crossix. Crossix will operate as an independent business unit under its current brand led by Crossix CEO Asaf Evenhaim.
Crossix delivers privacy-safe US patient data and an analytics platform to help maximize media and marketing effectiveness.
“Crossix has been the pioneer in patient data, privacy, and analytics,” said Veeva founder and CEO Peter Gassner. “As we look toward the future of a more patient-centric healthcare system, Asaf and I are excited to join forces to help the industry deliver better patient outcomes.”
The Crossix analytics platform provides technology that connects health and non-health data for more than 300 million US patients to drive greater marketing effectiveness. Data includes Rx, OTC, clinical, claims, consumer, hospital, media data, and more – all of which are protected by privacy safeguards.
“Veeva’s acquisition of Crossix is great for our customers and employees. It allows Crossix to join a proven technology leader and advance our solutions for the industry,” said Mr. Evenhaim. “Most importantly, our companies share a commitment to innovation and have a common way of working that values integrity, long-term thinking, and customer success.”
Crossix will remain headquartered in New York and continue operations in Israel and Belarus.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.